Tempus AI, Inc. - Class A Common Stock (TEM)

Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space.

Equities turned bullish this week on renewed hopes for progress in trade deals; next week's inflation readings could be a market mover

CoreWeave is arguably the most talked-about new stock in 2025. What is to make of this AI cloud infrastructure firm with a significant investment from NVIDIA?

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point to significant upside potential.

On Wednesday, May 7, 2025, Cathie Wood's Ark Invest Pours $24M Into Nvidia and AMD While Offloading $38.8M in Palantir Shares.

Tempus AI shares rose after a Q1 beat, as an analyst highlighted its AI-driven growth, expanding pharma deals, and $1B+ contract value.

Nancy Pelosi's investments over 11 years have outperformed the 'Oracle of Omaha', Warren Buffett's Berkshire Hathaway.

Tempus AI reassured investors that its major pharma contracts remain strong despite funding and tariff pressures.

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology."

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision medicine and patient care company reports a first-quarter adjusted loss of 24 cents per share, beating analyst estimates for a loss of 27 cents per share, according to Benzinga Pro.

Tempus AI shares are trading lower by 1.3% Tuesday afternoon. The company will report its Q1 earnings after Tuesday's market close.

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. because "it's going to be a great position."

Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics.

Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with AstraZeneca PLC (NASDAQ:AZN) and Pathos AI.

April 23, 2025 – Tempus AI, Inc. (NASDAQ: TEM), a leading precision medicine company leveraging artificial intelligence (AI) for diagnostic and therapeutic advancements, saw its Class A Common Stock soar by 16.07% in morning trading today, reaching $50.18 per share. The significant spike, accompanied by a trading volume of